SLC5A2 and heart failure: There are several candidates for optimizing plasma volume therapy, such as renin angiotensin aldosterone inhibitors, ferric carboxymaltose, and sodium-glucose cotransporter 2 inhibitors in patients with heart failure [16, 26–28].